Medical Equipment

Increasing Prevalence Of Cancer Is Fueling The Growth Of The Market Due To Rising Diagnosis Rates And Growing Demand For Targeted Treatments Is Supporting Development Across The PD-L1 And PIK3CA Testing Market

May 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The PD-L1 And PIK3CA Testing Market Change Between 2026 And 2030?

The market size for pd-l1 and pik3ca testing has experienced swift expansion in recent years. It is anticipated to grow from $1.67 billion in 2025 to $1.93 billion in 2026, with a compound annual growth rate (CAGR) of 15.5%. The historical growth can be ascribed to the creation of pd-l1 and pik3ca assays, their implementation in clinical trials, the increasing prevalence of cancer, advancements in molecular diagnostics, and a heightened awareness of personalized therapy.

The pd-l1 and pik3ca testing market is poised for significant expansion over the coming years. This market is projected to reach $3.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. Factors driving this growth during the forecast period include the incorporation of AI into biomarker identification, the increasing adoption of liquid biopsy applications, advancements in precision oncology, collaborations between diagnostic and pharmaceutical firms, and regulatory green lights for advanced assays. Key trends anticipated during this period encompass targeted cancer biomarker screening, AI-powered mutation analysis, wider acceptance of liquid biopsy, synergy with drug development processes, and high-volume genomic screening.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28289&type=smp

Which Growth Drivers Are Expected To Support The PD-L1 And PIK3CA Testing Market Forward?

The increasing incidence of cancer is expected to fuel the expansion of the PD-L1 and PIK3CA testing market going forward. Cancer is a condition marked by the unregulated proliferation and dissemination of atypical cells in the body, which can infiltrate adjacent tissues and potentially spread to other areas. The widespread occurrence of cancer is attributed to growing lifestyle-related hazards and an aging population, leading to higher diagnosis rates and a greater demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing assist in the management of cancer by allowing for accurate diagnosis and guiding personalized medicines, which helps tailor treatment plans for individual patients and improves clinical outcomes. For instance, in September 2024, the American Cancer Society, a US-based non-profit organization, reported that global cancer cases in men are projected to rise by 84% by 2029, increasing from 10.3 million in 2022 to 19 million. Consequently, the rising prevalence of cancer is propelling the growth of the PD-L1 and PIK3CA testing market.

How Does Segment Analysis Break Down The PD-L1 And PIK3CA Testing Market Structure?

The pd-l1 and pik3ca testing market covered in this report is segmented –

1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction

2) By Sample Type: Tissue Samples, Liquid Biopsy Samples

3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications

4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies

Subsegments:

1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis

2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing

3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction

What Trends Are Influencing The PD-L1 And PIK3CA Testing Market?

Leading companies active in the PD-L1 and PIK3CA testing market are concentrating on technological innovations, such as the incorporation of companion diagnostic integration, to improve the precision of therapeutic targeting, boost treatment effectiveness, and support personalized medicine strategies in oncology. This integration refers to sophisticated, technology-driven testing systems designed alongside targeted medicines to identify patient populations most likely to benefit from specific treatments based on their biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, launched Itovebi (inavolisib) in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The Food and Drug Administration (FDA), a US-based federal agency, approved this regimen, an approval stemming from the pivotal Phase III INAVO120 study, which showed more than double the progression-free survival when compared with palbociclib and fulvestrant alone. This represents Roche’s first targeted therapy for HR-positive disease and incorporates a companion diagnostic to pinpoint eligible patients, signifying a major advance in precision medicine for a patient population facing limited first-line treatment options.

Which Organizations Are Involved In The PD-L1 And PIK3CA Testing Market?

Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

Access The Complete PD-L1 And PIK3CA Testing Market Report:

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Which Region Stands As The Largest Contributor To The PD-L1 And PIK3CA Testing Market?

North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized PD-L1 And PIK3CA Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Browse Through More Reports Similar to the Global PD-L1 And PIK3CA Testing Market 2026, By The Business Research Company

Hpv Testing And Pap Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report

D Dimer Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report

Direct To Consumer Dtc Laboratory Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-laboratory-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795